<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01235117</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000688119</org_study_id>
    <secondary_id>CTRU-CMML-201</secondary_id>
    <secondary_id>ISRCTN-21428905</secondary_id>
    <secondary_id>EUDRACT-2008-006349-23</secondary_id>
    <secondary_id>LEEDS-HM08/8540</secondary_id>
    <secondary_id>EU-21082</secondary_id>
    <nct_id>NCT01235117</nct_id>
  </id_info>
  <brief_title>Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>A Phase 2 Study of Azacitidine in Chronic Myelomonocytic Leukemia (CMML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop&#xD;
      the growth of cancer cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying the side effects of azacitidine and to see how well&#xD;
      it works in treating patients with chronic myelomonocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the safety and tolerability of azacitidine in patients with chronic&#xD;
           myelomonocytic leukemia (CMML).&#xD;
&#xD;
        -  To assess the overall response rate in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the incidence of clinical remission/complete remission or partial response in&#xD;
           these patients.&#xD;
&#xD;
        -  To assess hematological improvement in patients treated with this drug.&#xD;
&#xD;
        -  To assess the overall survival of patients treated with this drug.&#xD;
&#xD;
        -  To assess progression-free survival of patients treated with this drug.&#xD;
&#xD;
        -  To assess the time to acute myeloid leukemia (AML) transformation of CMML.&#xD;
&#xD;
        -  To assess the time to death or AML transformation of CMML.&#xD;
&#xD;
        -  To assess the biological correlates.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive azacitidine subcutaneously on days 1-5 and 8-9. Treatment repeats every 4&#xD;
      weeks for at least 6 courses in the absence of loss of response/disease progression or&#xD;
      unacceptable toxicity. Patients undergo response evaluation after 6 courses or the last&#xD;
      course of treatment. Responders may continue azacitidine until loss of response/disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Some patients undergo blood, bone marrow, and buccal swab sample collection periodically for&#xD;
      correlative studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 1 month.&#xD;
&#xD;
      Peer Reviewed and Funded or Endorsed by Cancer Research UK&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical remission/complete remission or partial response according to International Working Group (IWG) criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematological improvement according to IWG criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to acute myeloid leukemia (AML) transformation of CMML</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to death or AML transformation of CMML</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlates</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  All chronic myelomonocytic leukemia (CMML)-2 patients&#xD;
&#xD;
               -  CMML-1 patients meeting any of the following criteria:&#xD;
&#xD;
                    -  Symptomatic bone marrow failure/myeloproliferation defined as any of the&#xD;
                       following:&#xD;
&#xD;
                         -  Red cell transfusion dependence and pre-transfusion hemoglobin &lt; 9.0&#xD;
                            g/dL&#xD;
&#xD;
                         -  Symptomatic anemia (hemoglobin &lt; 11.5 g/dL)&#xD;
&#xD;
                         -  Thrombocytopenia (platelet count &lt; 50 x 10^9/L)&#xD;
&#xD;
                         -  Symptomatic bleeding due to platelet functional defect or disseminated&#xD;
                            intravascular coagulation (DIC)/fibrinolysis&#xD;
&#xD;
                         -  White cell count (WCC) &gt; 50 x 10^9/L&#xD;
&#xD;
                    -  Düsseldorf Score of intermediate or high risk for proliferative CMML-1&#xD;
                       (i.e., WCC &gt; 12 x 10^9/L)&#xD;
&#xD;
                    -  International Prognostic Scoring System (IPSS) score of intermediate-2 or&#xD;
                       high risk for non-proliferative CMML-1 (i.e., WCC &lt; 12 x 10^9/L)&#xD;
&#xD;
                    -  Systemic symptoms including weight loss with no alternative explanation (10%&#xD;
                       of baseline weight within the past 6 months)&#xD;
&#xD;
                    -  Symptomatic splenomegaly&#xD;
&#xD;
                    -  Symptomatic extramedullary involvement (e.g. skin infiltration or serous&#xD;
                       effusions)&#xD;
&#xD;
          -  No CMML with eosinophilia and 5q33 abnormality&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Creatinine ≤ 2 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative urine pregnancy test&#xD;
&#xD;
          -  Fertile patients must use at least 2 forms of effective contraception during study and&#xD;
             for 3 months after completion of study therapy&#xD;
&#xD;
          -  No other active malignant disease including basal cell or squamous cell carcinoma of&#xD;
             the skin&#xD;
&#xD;
          -  No known HIV or infectious hepatitis B or hepatitis C&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No known hypersensitivity to azacitidine or mannitol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 28 days since other prior experimental drug or therapy&#xD;
&#xD;
          -  No prior chemotherapy for this disease except hydroxycarbamide&#xD;
&#xD;
          -  No other concurrent anticancer or investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David T. Bowen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leeds Cancer Centre at St. James's University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <study_first_submitted>November 4, 2010</study_first_submitted>
  <study_first_submitted_qc>November 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2010</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

